Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Sattler

Showing results (101-110 of 131) with videos related to

Pageof 14
Sort By:
Molecular Therapy. Oncology|March 24, 2025
Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy synergy between CARM1 inhibition and IMiDsWei Ni, Swati Garg, Basudev Chowdhury, et al.
Journal of Medical Virology|September 19, 2022
Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapyRuthMabel Boytz, Mikołaj Słabicki, Sita Ramaswamy, et al.
Cancers|December 30, 2020
Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)Moshe Lapidot, Abigail E Case, Dalia Larios, et al.
Molecular Therapy. Oncology|April 15, 2025
Erratum: Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapyWei Ni, Swati Garg, Basudev Chowdhury, et al.
Cell Reports. Medicine|June 16, 2026
The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided careAritro Nath, Jyoti Malhotra, Isa Mambetsariev, et al.
Leukemia|July 30, 2021
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2Jing Yang, Ellen L Weisberg, Xiaoxi Liu, et al.
Leukemia|September 7, 2021
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Leukemia|May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Molecular Cancer Therapeutics|July 25, 2015
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097Ellen Weisberg, Ensar Halilovic, Vesselina G Cooke, et al.
Plos One|February 4, 2010
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinasesYi-Hung Carol Tan, Soundararajan Krishnaswamy, Suvobroto Nandi, et al.
Pageof 14

Showing results (101-110 of 131) with videos related to

Sort By:
Pageof 14
Molecular Therapy. Oncology|March 24, 2025
Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy synergy between CARM1 inhibition and IMiDsWei Ni, Swati Garg, Basudev Chowdhury, et al.
Journal of Medical Virology|September 19, 2022
Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapyRuthMabel Boytz, Mikołaj Słabicki, Sita Ramaswamy, et al.
Cancers|December 30, 2020
Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)Moshe Lapidot, Abigail E Case, Dalia Larios, et al.
Molecular Therapy. Oncology|April 15, 2025
Erratum: Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapyWei Ni, Swati Garg, Basudev Chowdhury, et al.
Cell Reports. Medicine|June 16, 2026
The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided careAritro Nath, Jyoti Malhotra, Isa Mambetsariev, et al.
Leukemia|July 30, 2021
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2Jing Yang, Ellen L Weisberg, Xiaoxi Liu, et al.
Leukemia|September 7, 2021
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Leukemia|May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Molecular Cancer Therapeutics|July 25, 2015
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097Ellen Weisberg, Ensar Halilovic, Vesselina G Cooke, et al.
Plos One|February 4, 2010
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinasesYi-Hung Carol Tan, Soundararajan Krishnaswamy, Suvobroto Nandi, et al.
Pageof 14